Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa

20th January 2026 Uncategorised 0

The U.S. Supreme Court will hear a case involving the “skinny label” practice of generic drugmakers, with its review particularly relating to Hikma’s marketing of its generic version of Amarin’s Vascepa.

More: Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa
Source: fierce